28Jan 2025
Biologic Therapy and Surgery for Nasal Polyps in EGPA

Biologic Therapy and Surgery for Nasal Polyps in EGPA

Mepolizumab was the most common biologic for eosinophilic granulomatosis with polyangiitis (EGPA) patients with nasal polyps (NP). 88.75% of 80 patients required endoscopic sinus surgery (ESS), with 47.5% undergoing ESS after biologic therapy. Multidisciplinary treatment combining biologics and surgery showed promising results in managing recalcitrant NP. Despite the use of biologics, a significant portion of patients still needed ESS for effective symptom control.

  • #ent

Like

Save

Share